CohBar Inc
Change company Symbol lookup
Select an option...
CWBR CohBar Inc
EA Electronic Arts Inc
DAC Danaos Corp
EMF Templeton Emerging Markets Fund Inc.
CVS CVS Health Corp
DIS Walt Disney Co
MPC Marathon Petroleum Corp
NOK Nokia Oyj
NVAX Novavax Inc
APT Alpha Pro Tech Ltd
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

CohBar, Inc. (CohBar), is a clinical stage biotechnology company. The Company is focused on the research and development of mitochondria-based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The Company has discovered more than 100 mitochondrial-derived peptides and is focused on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, cancer, fibrotic diseases including idiopathic pulmonary fibrosis (IPF), type 2 diabetes (T2D), cardiovascular and neurodegenerative diseases. The Company’s lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs that include MBT5 Analogs (CXCR4 Antagonists) for Cancer and Other Disease Indicatio, MBT2 Analogs for Fibrotic Diseases, MBT3 Analog for Cancer Immunotherapy and CB5064 Analogs for Type 2 Diabetes.

Price
Delayed
$1.63
Day's Change
0.08 (5.16%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.64
Day's Low
1.57
Volume
(Above Average)

Today's volume of 76,782 shares is on pace to be greater than CWBR's 10-day average volume of 137,439 shares.

76,782

Display:

Providers:

UpdateCancel
4 providers

No article found.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.